



Excess Fat Tissue May Be The Most Significant Atherosclerotic Risk Factor In The Body

Mehmet Rami Helvaci^{1*}, Elif Helvaci², Irem Sultan Kamalak², Yusuf Aydin¹, Leyla Yilmaz Aydin³, Alper Sevinc¹, Celaletdin Camci¹, Abdulrazak Abyad⁴, Lesley Pocock⁵

¹Specialist of Internal Medicine, MD, Turkey.

²Manager of Writing and Statistics, Turkey.

³Specialist of Pulmonary Medicine, MD, Turkey.

⁴Middle-East Academy for Medicine of Aging, MD, Lebanon.

⁵Medi-WORLD International, Australia.

Article Info

Received: August 20, 2025

Accepted: September 02, 2025

Published: September 10, 2025

***Corresponding author:** Mehmet Rami Helvaci, Specialist of Internal Medicine, MD, Turkey.

Citation: Mehmet R Helvaci, Helvaci E, Irem S Kamalak, Aydin Y, Leyla Y Aydin, Sevinc A, Camci C, Abdulrazak Abyad, Pocock L., (2025) "Excess Fat Tissue May Be The Most Significant Atherosclerotic Risk Factor In The Body." International Journal of Clinical Cardiology and Cardiovascular, 5(1). DOI: 10.61148/2836-2837/IJCCCI.

Copyright: © 2025 Mehmet Rami Helvaci. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract:

Background: Atherosclerosis may be the main cause of aging and shortened survival in human being.

Methods: All patients with sickle cell diseases (SCD) were included.

Results: We studied 222 males and 212 females with similar mean ages (30.8 vs 30.3 years, $p>0.05$, respectively). Smoking (23.8% vs 6.1%, $p<0.001$), alcohol (4.9% vs 0.4%, $p<0.001$), transfused red blood cells (RBC) in their lives (48.1 vs 28.5 units, $p=0.000$), disseminated teeth losses (5.4% vs 1.4%, $p<0.001$), ileus (7.2% vs 1.4%, $p<0.001$), stroke (12.1% vs 7.5%, $p<0.05$), chronic renal disease (9.9% vs 6.1%, $p<0.05$), cirrhosis (8.1% vs 1.8%, $p<0.001$), chronic obstructive pulmonary disease (25.2% vs 7.0%, $p<0.001$), coronary heart disease (18.0% vs 13.2%, $p<0.05$), leg ulcers (19.8% vs 7.0%, $p<0.001$), and clubbing (14.8% vs 6.6%, $p<0.001$) were all higher in males.

Conclusion: As an accelerated atherosclerotic process, hardened RBC-induced capillary endothelial damage initiated at birth terminates with multiorgan insufficiencies in early decades in the SCD. Diabetes mellitus (DM) may actually be one of the atherosclerotic endpoints of the pancreas. Although all of the above atherosclerotic consequences are frequent in SCD, we have not detected any case of DM probably due to the significantly lower body mass indexes of them. Similarly, just 20% of elderly have DM, but 55% of patients with DM are obese. So excess fat tissue may be much more significant than smoking, alcohol, or other chronic inflammatory or infectious processes for systemic atherosclerosis. Acarbose and metformin are safe, cheap, oral, long-term used, and effective drugs for loss of excess fat tissue.

Keywords: sickle cell diseases, excess fat tissue, capillary endothelial inflammation, atherosclerotic endpoints, diabetes mellitus, acarbose, metformin

Introduction

Chronic endothelial damage initiating at birth may be the most significant reason of aging and shortened survival via the atherosclerotic consequences in human body (1).

higher blood pressures (BP) of the arterial system may be the strongest accelerating factor via the repeated injuries on vascular endothelium. Probably, whole afferent vasculature including capillaries are chiefly involved in the destructive process. Therefore venosclerosis is not a significant health problem. Due to the chronic endothelial damage, inflammation, edema, and fibrosis, vascular walls thicken, their lumens narrow, and they lose their elastic natures, which terminally reduce blood supply to the end-organs, and increase systolic and decrease diastolic BP further. Some of the well-known accelerating factors of the inflammatory process are physical and mental inactivity, emotional stresses, animal-rich diet, smoking, alcohol, excess fat tissue, chronic inflammation, prolonged infection, and cancers for the development of atherosclerotic endpoints including obesity, hypertension (HT), diabetes mellitus (DM), chronic renal disease (CRD), coronary heart disease (CHD), cirrhosis, chronic obstructive pulmonary disease (COPD), peripheral artery disease (PAD), stroke, abdominal angina, osteoporosis, dementia, early aging, and shortened survival (2, 3). Although early withdrawal of the accelerating factors can delay the consequences, the endothelial changes can not be reversed, completely due to fibrotic natures. The accelerating factor and atherosclerotic endpoints of the destructive process on vascular endothelium have been researched under the titles of metabolic syndrome, aging syndrome, and accelerated endothelial damage syndrome in the literature, extensively (4-6). Similarly, sickle cell diseases (SCD) are highly catastrophic process on vascular endothelium initiating at birth and terminating with an accelerated atherosclerosis-induced multiorgan insufficiencies in much earlier decades (7, 8). Hemoglobin S causes loss of elastic and biconcave disc shaped structures of red blood cells (RBC). Loss of elasticity instead of shape may be the chief cause because sickling is rare in peripheral blood samples of patients with associated thalassemia minors (TM), and survival is not affected in hereditary spherocytosis or elliptocytosis in human being. Loss of elasticity is present during whole lifespan, but exaggerated with inflammation, infection, cancer, and additional stresses. The hardened RBC-induced chronic endothelial damage, inflammation, edema, and fibrosis terminate with tissue hypoxia in whole body (9). As a difference from other causes of chronic endothelial damage, SCD keep vascular endothelium especially at the capillary level because the capillary system is the main distributor of the hardened RBC in the body (10, 11). The hardened RBC-induced chronic endothelial damage builds up an accelerated atherosclerosis in much earlier decades. Vascular narrowing and occlusions-induced tissue ischemia and end-organ insufficiencies are the terminal consequences, so the mean life expectancy is decreased 30 years or more in the SCD because we have patients with the age of 96 years without the SCD but just with the age of 59 years with the SCD in our clinic (8).

Material and methods

The study was performed in the Medical Faculty of the Mustafa Kemal University between March 2007 and June 2016. All cases with the SCD were included. SCD are diagnosed with the hemoglobin electrophoresis performed via high performance liquid chromatography (HPLC). Smoking, alcohol, acute painful crises per year, transfused units of RBC in their lifespans, leg ulcers, stroke, surgical procedures, deep venous thrombosis (DVT), epilepsy, and priapism were researched in all patients. Patients with

a history of one pack-year and one drink-year were accepted as smoker and drinkers, respectively. A full physical examination was performed by the Same Internist, and cases with disseminated teeth losses (<20 teeth present) were detected. Patients with acute painful crisis or any other inflammatory or infectious process were treated at first, and the laboratory tests and clinical measurements were performed on the silent phase. Check up procedures including serum iron, iron binding capacity, ferritin, creatinine, liver function tests, markers of hepatitis viruses A, B, and C, a posterior-anterior chest x-ray film, an electrocardiogram, a Doppler echocardiogram both to evaluate cardiac walls and valves and to measure systolic BP of pulmonary artery, an abdominal ultrasonography, a venous Doppler ultrasonography of the lower limbs, a computed tomography (CT) of brain, and magnetic resonance imagings (MRI) of brain and hips were performed. Other bones for avascular necrosis were scanned according to the patients' complaints. So avascular necrosis of bones was diagnosed via MRI (12). Associated TM were detected with serum iron, iron binding capacity, ferritin, and hemoglobin electrophoresis performed via HPLC since SCD with associated TM come with milder clinics than the sickle cell anemia (SCA) (Hb SS) alone (13). Systolic BP of the pulmonary artery of 40 mmHg or greater are accepted as pulmonary hypertension (14). Hepatic cirrhosis is diagnosed with full physical examination, laboratory parameters, and ultrasonographic evaluation of the liver. The criterion for diagnosis of COPD is a post-bronchodilator forced expiratory volume in one second/forced vital capacity of lower than 70% (15). Acute chest syndrome (ACS) is diagnosed clinically with the presence of new infiltrates on chest x-ray film, fever, cough, sputum, dyspnea, and hypoxia (16). An x-ray film of abdomen in upright position was taken just in patients with abdominal distention or discomfort, vomiting, obstipation, or lack of bowel movement, and ileus is diagnosed with gaseous distention of isolated segments of bowel, vomiting, obstipation, cramps, and with the absence of peristaltic activity. CRD is diagnosed with a continuously elevated serum creatinine level of 1.3 mg/dL or greater in males and 1.2 mg/dL or higher in females. Clubbing is diagnosed with the ratio of distal phalangeal diameter to interphalangeal diameter of greater than 1.0, and with the presence of Schamroth's sign (17, 18). An exercise electrocardiogram is taken in case of an abnormal electrocardiogram and/or angina pectoris. Coronary angiography is performed in case of a positive exercise electrocardiogram. Finally, CHD was diagnosed either angiographically or with the Doppler echocardiographic findings as movement disorders in the heart walls. Rheumatic heart disease is diagnosed with the echocardiographic findings, too. Stroke was diagnosed by the CT and/or MRI of the brain. Sickle cell retinopathy is diagnosed with ophthalmologic examination in case of visual complaints. Mann-Whitney U test, Independent-Samples t test, and comparison of proportions were used as the methods of statistical analyses.

Results

We included 222 males and 212 females with similar mean ages (30.8 vs 30.3 years, $p>0.05$, respectively) into the study, and there was not any patient above the age of 59 years. Associated TM were detected with similar prevalences in both genders (72.5% vs 67.9%, $p>0.05$, respectively). Both smoking (23.8% vs 6.1%) and alcohol (4.9% vs 0.4%) were higher in males ($p<0.001$ for both) (Table 1). Transfused units of RBC in their lives (48.1 vs 28.5, $p=0.000$), disseminated teeth losses (5.4% vs 1.4%, $p<0.001$), ileus

(7.2% vs 1.4%, $p<0.001$), CRD (9.9% vs 6.1%, $p<0.05$), hepatic cirrhosis (8.1% vs 1.8%, $p<0.001$), COPD (25.2% vs 7.0%, $p<0.001$), CHD (18.0% vs 13.2%, $p<0.05$), leg ulcers (19.8% vs 7.0%, $p<0.001$), digital clubbing (14.8% vs 6.6%, $p<0.001$), and stroke (12.1% vs 7.5%, $p<0.05$) were all higher in males, significantly. Although the mean age of mortality (30.2 vs 33.3 years) was lower in males, the difference was nonsignificant, probably due to the small sample sizes of the study (**Table 2**). On the other hand, mean ages of the atherosclerotic consequences were shown in **Table 3**.

Table 1: Characteristic features of the study patients

Variables	Males with the SCD*	<i>p</i> -value	Females with the SCD
Prevalence	51.1% (222)	Ns†	48.8% (212)
Mean age (year)	30.8 ± 10.0 (5-58)	Ns	30.3 ± 9.9 (8-59)
Associated TM‡	72.5% (161)	Ns	67.9% (144)
<u>Smoking</u>	<u>23.8% (53)</u>	<u><0.001</u>	<u>6.1% (13)</u>
<u>Alcoholism</u>	<u>4.9% (11)</u>	<u><0.001</u>	<u>0.4% (1)</u>

*Sickle cell diseases †Nonsignificant ($p>0.05$) ‡Thalassemia minors

Table 2: Associated pathologies of the study patients

Variables	Males with the SCD*	<i>p</i> -value	Females with the SCD
Painful crises per year	5.0 ± 7.1 (0-36)	Ns†	4.9 ± 8.6 (0-52)
<u>Transfused units of RBC‡</u>	<u>48.1 ± 61.8 (0-434)</u>	<u>0.000</u>	<u>28.5 ± 35.8 (0-206)</u>
<u>Disseminated teeth losses (<20 teeth present)</u>	<u>5.4% (12)</u>	<u><0.001</u>	<u>1.4% (3)</u>
<u>CHD§</u>	<u>18.0% (40)</u>	<u><0.05</u>	<u>13.2% (28)</u>
<u>Cirrhosis</u>	<u>8.1% (18)</u>	<u><0.001</u>	<u>1.8% (4)</u>
<u>COPD¶</u>	<u>25.2% (56)</u>	<u><0.001</u>	<u>7.0% (15)</u>
<u>Ileus</u>	<u>7.2% (16)</u>	<u><0.001</u>	<u>1.4% (3)</u>
<u>Leg ulcers</u>	<u>19.8% (44)</u>	<u><0.001</u>	<u>7.0% (15)</u>
<u>Digital clubbing</u>	<u>14.8% (33)</u>	<u><0.001</u>	<u>6.6% (14)</u>
<u>CRD**</u>	<u>9.9% (22)</u>	<u><0.05</u>	<u>6.1% (13)</u>
<u>Stroke</u>	<u>12.1% (27)</u>	<u><0.05</u>	<u>7.5% (16)</u>
PHT***	12.6% (28)	Ns	11.7% (25)
Autosplenectomy	50.4% (112)	Ns	53.3% (113)
DVT**** and/or varices and/or telangiectasias	9.0% (20)	Ns	6.6% (14)
Rheumatic heart disease	6.7% (15)	Ns	5.6% (12)
Avascular necrosis of bones	24.3% (54)	Ns	25.4% (54)
Sickle cell retinopathy	0.9% (2)	Ns	0.9% (2)
Epilepsy	2.7% (6)	Ns	2.3% (5)
ACS*****	2.7% (6)	Ns	3.7% (8)
Mortality	7.6% (17)	Ns	6.6% (14)
Mean age of mortality (year)	30.2 ± 8.4 (19-50)	Ns	33.3 ± 9.2 (19-47)

*Sickle cell diseases †Nonsignificant ($p>0.05$) ‡Red blood cells §Coronary heart disease ¶Chronic obstructive pulmonary disease **Chronic renal disease ***Pulmonary hypertension ****Deep venous thrombosis *****Acute chest syndrome

Table 3: Mean ages of endpoints of the sickle cell diseases

Variables	Mean age (year)
Ileus	29.8 ± 9.8 (18-53)

Hepatomegaly	30.2 ± 9.5 (5-59)
ACS*	30.3 ± 10.0 (5-59)
Sickle cell retinopathy	31.5 ± 10.8 (21-46)
Rheumatic heart disease	31.9 ± 8.4 (20-49)
Autosplenectomy	32.5 ± 9.5 (15-59)
Disseminated teeth losses (<20 teeth present)	32.6 ± 12.7 (11-58)
Avascular necrosis of bones	32.8 ± 9.8 (13-58)
Epilepsy	33.2 ± 11.6 (18-54)
Priapism	33.4 ± 7.9 (18-51)
Left lobe hypertrophy of the liver	33.4 ± 10.7 (19-56)
Stroke	33.5 ± 11.9 (9-58)
COPD†	33.6 ± 9.2 (13-58)
PHT‡	34.0 ± 10.0 (18-56)
Leg ulcers	35.3 ± 8.8 (17-58)
Digital clubbing	35.4 ± 10.7 (18-56)
CHD§	35.7 ± 10.8 (17-59)
DVT¶ and/or varices and/or telangiectasias	37.0 ± 8.4 (17-50)
Cirrhosis	37.0 ± 11.5 (19-56)
CRD**	39.4 ± 9.7 (19-59)

*Acute chest syndrome †Chronic obstructive pulmonary disease ‡Pulmonary hypertension §Coronary heart disease ¶Deep venous thrombosis **Chronic renal disease

Discussion

Excess fat tissue may be the most significant cause of vasculitis in human body. DM may actually be one of the atherosclerotic endpoints in human being. Although all of the atherosclerotic endpoints are frequent in the SCD, we have not detected any case of DM, probably due to the significantly lower mean body mass indexes (BMI) (10). The mean body weights and BMI were 57.8 vs 71.6 kg and 20.7 vs 24.9 kg/m² in the SCD and control cases, respectively with the mean age of 28.6 years ($p=0.000$ for both) (10). Additionally, the heaviest patient was 83 kg in weight in the SCD whereas 111 kg in the control groups ($p=0.000$) (10).

Interestingly, the mean body heights were similar in both groups (166.1 vs 168.5 cm, respectively, $p>0.05$) which may powerfully indicate that body height is determined, genetically (10). Similarly, just 20% of elderly have DM, but 55% of patients with DM are

obese. So excess fat tissue may be much more significant than smoking, alcohol, or other chronic inflammatory or infectious processes for systemic atherosclerosis. Excess fat tissue leads to a chronic and low-grade inflammation on vascular endothelium, and risk of death from all causes increases parallel to the range of excess fat tissue (19). The low-grade chronic inflammation may also cause genetic changes on the endothelial cells, and the systemic atherosclerosis may even decrease the clearance of malignant cells by the natural killers terminating with the cancers (20). The chronic inflammatory process is characterized by lipid-induced injury, invasion of macrophages, proliferation of smooth muscle cells, endothelial dysfunction, and increased atherogenicity (21, 22). Excess fat tissue is considered as a strong factor for controlling of C-reactive protein (CRP) because the fat tissue produces biologically active leptin, tumor necrosis factor- α , plasminogen activator inhibitor-1, and adiponectin-like cytokines (23, 24). On the other hand, excess fat tissue will also aggravate

myocardial hypertrophy and decrease cardiac compliance further. Fasting plasma glucose (FPG) and serum cholesterol increased and high density lipoproteins (HDL) decreased parallel to the increased BMI (25). Similarly, the prevalences of CHD and stroke increased parallel to the increased BMI (26). Eventually, the risk of death from all causes increased parallel to the severity of excess fat tissue in all age groups, and the cases with underweight may even have lower biological ages and longer survival (27). Similarly, calorie restriction prolongs survival and retards age-related chronic illnesses in human being (28).

Smoking may be the second most common cause of vasculitis all over the body. It may cause a systemic inflammation on vascular endothelium terminating with atherosclerotic end-organ insufficiencies in early decades (29). Its atherosclerotic effect is obvious in the Buerger's disease and COPD (30). Buerger's disease is an obliterative vasculitis in the small and medium-sized arteries and veins, and it has never been reported in the absence of smoking. Its characteristic features are chemical toxicity, inflammation, fibrosis, and narrowing and occlusions of arteries and veins. Claudication is the most significant symptom with a severe pain in feet and hands caused by insufficient blood supply, particularly by walking in the feet. It typically begins in extremities but may also radiate to central areas in advanced cases. Numbness or tingling of the limbs is also common. Skin ulcerations and gangrene of fingers or toes are the irreversible endpoints. Similar to the venous ulcers, diabetic ulcers, leg ulcers of the SCD, digital clubbing, onychomycosis, and delayed wound and fracture healings of the lower extremities, pooling of blood due to the gravity may be the major cause in the development of Buerger's disease, particularly in the lower extremities. Multiple narrowing and occlusions in the arm and legs are diagnostic in the angiogram. Skin biopsies may be risky, because a poorly perfused area will not heal, completely. Although most patients are heavy smokers, the limited smoking history of some patients may support the hypothesis that Buerger's disease may be an autoimmune reaction triggered by some constituent of tobacco. Although the only treatment way is complete cessation of smoking, the already developed narrowing and occlusions are irreversible. Due to the well-known role of inflammation, anti-inflammatory dose of aspirin in addition to the low-dose warfarin may be beneficial in prevention of microvascular infarctions. On the other hand, FPG and HDL may be negative whereas triglycerides, low density lipoproteins (LDL), erythrocyte sedimentation rate, and CRP positive APR in smokers (31). Similarly, smoking was associated with the lower BMI values due to the systemic inflammatory effects (32, 33). An increased heart rate was detected just after smoking even at rest (34). Nicotine supplied by patch after smoking cessation decreased caloric intake in a dose-related manner (35). Nicotine may lengthen intermeal time, and decrease amount of meal eaten (36). Smoking may be associated with a postcessation weight gain, but the risk is the highest during the first year, and decreases with the following years (37). Although the CHD was detected with similar prevalences in both genders, prevalences of smoking and COPD were higher in males against the higher white coat hypertension, BMI, LDL, triglycerides, HT, and DM in females (38). The risk of myocardial infarction is increased three-fold in men and six-fold in women with smoking, so smoking may be more harmful for women probably due to the higher BMI in them (39). Chemical

toxicity of smoking can affect various organ systems. For instance, it is usually associated with depression, irritable bowel syndrome (IBS), chronic gastritis, hemorrhoids, and urolithiasis with several possible mechanisms (40). First of all, smoking may have some anxiolytic properties. Secondly, smoking-induced vascular inflammation may disturb epithelial absorption and excretion in the gastrointestinal (GI) and genitourinary (GU) tracts (41). Thirdly, diarrheal losses-induced urinary changes may cause urolithiasis (42). Fourthly, smoking-induced sympathetic nervous system activation may cause motility problems in the GI and GU tracts terminating with IBS and urolithiasis. Finally, immunosuppression secondary to smoking may terminate with the GI and GU tract infections and urolithiasis since some types of bacteria can provoke urinary supersaturation, and modify the environment to form crystal deposits. Actually, 10% of urinary stones are struvite stones which are built by magnesium ammonium phosphate produced by the urease producing bacteria. As a result, urolithiasis was seen in 17.9% of cases with IBS and 11.6% of cases without ($p < 0.01$) (40).

CHD is the other major cause of death in the human being together with the stroke. The most common triggering cause is the disruption of an atherosclerotic plaque in an epicardial coronary artery, which leads to a clotting cascade. The plaques are the gradual and unstable collection of lipids, fibrous tissue, and white blood cells (WBC), particularly the macrophages in arterial walls in decades of life. Stretching and relaxation of arteries with each heart beat increases mechanical shear stress on atheromas to rupture. After the myocardial infarction, a collagen scar tissue takes its place which may also cause life threatening arrhythmias because the scar tissue conducts electrical impulses more slowly. The difference in conduction velocity between the injured and uninjured tissues can trigger re-entry or a feedback loop that is believed to be the cause of lethal arrhythmias. Ventricular fibrillation is the most serious arrhythmia that is the leading cause of sudden cardiac death. It is an extremely fast and chaotic heart rhythm. Ventricular tachycardia may also cause sudden cardiac death that usually results in rapid heart rates preventing effective cardiac pumping. Cardiac output and BP may fall to dangerous levels which can lead to further coronary ischemia and extension of the infarct. This scar tissue may even cause ventricular aneurysm and rupture. Aging, physical inactivity, animal-rich diet, excess fat tissue, smoking, alcohol, emotional stress, prolonged infection, chronic inflammation, and cancers are important in atherosclerotic plaque formation. Moderate physical exercise is associated with a 50% reduced incidence of CHD (43). Probably, excess fat tissue may be the most important cause of CHD since there are nearly 20 kg of excess fat between the lower and upper borders of normal weight, 33 kg between the obesity, 66 kg between the morbid obesity ($\text{BMI} \geq 40 \text{ kg/m}^2$), and 81 kg between the super obesity ($\text{BMI} \geq 45 \text{ kg/m}^2$) in adults. In fact, there is a huge percentage of adults with heavier fat masses than their lean masses that brings a heavy stress both on the heart and brain.

Type 2 DM is the most common cause of blindness, non-traumatic amputation, and renal dialysis in adults. It is probably caused by insulin deficiency, insulin resistance, defective insulins, and/or defective insulin receptors. But excess fat tissue probably takes the major role in the development. Excess fat tissue in liver and pancreas are called as non-alcoholic fatty liver disease (NAFLD)

and non-alcoholic fatty pancreas disease (NAFPD). They are usually accepted as components of the metabolic syndrome. NAFLD progresses to steatohepatitis, cirrhosis, hepatocellular carcinoma, and hepatic failure. Blocking triglycerides secretion, subcellular lipid sequestration, lipolysis deficiency, enhanced lipogenesis, gluconeogenesis defects, or inhibition of fatty acid oxidation may be some of the development mechanisms (44). NAFLD may just be one of the atherosclerotic endpoints, and it is strongly associated with an accelerated atherosclerotic process not only in the liver instead all over the body. For example, NAFLD is seen in one-third of cases with hepatitis B virus-related chronic liver disease (45). Similarly, higher fatty liver ratios were observed in children with non-Hodgkin lymphomas (46). The liver density on contrast abdominopelvic CT of colorectal cancer patients was low which is consistent with NAFLD (47). As one of the acute phase reactants (APR), serum thrombopoietin levels increased in cases with NAFLD (48). Although serum levels of oxidizing agents including nitrate and advanced oxidation protein products increased, serum nitrite did not adequately increase as an antioxidant agent in cases with NAFLD (49). As a result, NAFLD is associated with an impaired carotid intima-media thickness (IMT) and flow-mediated dilation which are considered as early markers of systemic atherosclerosis (50). Carotid IMT was correlated with the BMI ($p < 0.001$), age ($p = 0.001$), and grade 2-3 NAFLD ($p < 0.001$) (51). Patients with NAFLD have more complex CHD, and carotid IMT and grade 2-3 NAFLD were associated with the severity of CHD ($p < 0.001$ for both) (51-53). Similarly, there were reductions in hepatic artery flow volume, portal vein flow volume, and total flow volume in contrast to the increased NAFLD (54). Parallel to the liver, there may be reductions in blood flow volume of pancreatic arteries in NAFPD which is the most common benign pathologic condition of pancreas in adults (55). NAFPD is frequently related with the aging, obesity, and insulin resistance (56). Replacement of more than 25% of pancreas by fat tissue is associated with systemic atherosclerosis and increased risk of type 2 DM (57). Insulin is stored in vacuoles in beta cells of islets of Langerhans all over the pancreas and released via exocytosis. Pancreatic fat infiltration may lead to a reduced insulin secretion (58). NAFPD can lead to exocrine pancreatic insufficiency by fat droplet accumulation in pancreatic acinar cells and consequent lipotoxicity, destruction of acinar cells by both inflammation and fatty replacement, and by negative paracrine effect of adipocytes (59). It may cause pancreatic fibrosis and cancers. The patients with NAFPD have a higher risk of type 2 DM (57), and newly diagnosed patients with type 2 DM have significantly greater pancreatic fat content (60). Type 2 DM may actually be the pancreatic fibrosis and cirrhosis. Age-related impairment of beta cells may actually be one of the atherosclerotic endpoints since 20% of elderly have type 2 DM, and just 55% of patients with type 2 DM are obese. Glucose tolerance progressively decreases with aging. It may be due to the progressively decreased physical and mental activity-induced excess fat tissue secreting adipokines. There is no term of malnutrition-related DM in the literature. Type 2 DM can be cured by gastric bypass surgery in 90% of morbid obese patients (61). The effect is not due to the weight loss instead decreased insulin requirement since it usually occurs just after days of surgery. This surgery reduced death rate from all causes by 40% (61). NAFPD is an independent risk factor for CHD, too (62). Similarly, the presence of NAFPD is associated

with increased aortic IMT and epicardial adipose tissue (63). According to our opinion, NAFLD, cirrhosis, NAFPD, and DM may just be some of the atherosclerotic endpoints (64).

Acute painful crises are the severest symptoms of the SCD. Although some authors reported that pain itself may not be life threatening directly, infections, medical or surgical emergencies, or emotional stresses are the most common precipitating factors of the crises (65). The increased basal metabolic rate during such stresses aggravates the sickling and capillary endothelial damage, inflammation, and edema terminating with tissue hypoxia and multiorgan insufficiencies. So the risk of mortality is much higher during such crises. Actually, each crisis may complicate with the following crises by leaving significant sequelae on the capillary endothelial system all over the body. After a period of time, the sequelae may terminate with multiorgan failures and sudden death with an acute painful crisis that may even be silent, clinically. Similarly, after a 20-year experience on such patients, the deaths seem sudden and unexpected events in the SCD. Unfortunately, most of the deaths develop just after the hospital admission, and majority of them are patients without hydroxyurea therapy (66, 67). Rapid RBC supports are usually life-saving for such patients, although preparation of RBC units for transfusion usually takes time. Beside that RBC supports in emergencies become much more difficult in terminal cases due to the repeated transfusions-induced blood group mismatch. Actually, transfusion of each unit of RBC complicates the following transfusions by means of the blood subgroup mismatch. Due to the significant efficacy of hydroxyurea therapy, RBC transfusions should be kept just for acute events and emergencies in the SCD (66-68). According to our experiences, simple and repeated transfusions are superior to RBC exchange (69, 70). First of all, preparation of one or two units of RBC suspensions in each time rather than preparation of six units or higher provides time to clinicians to prepare more units by preventing sudden death of such high-risk patients. Secondly, transfusions of one or two units of RBC suspensions in each time decrease the severity of pain, and relax anxiety of the patients and their relatives since RBC transfusions probably have the strongest analgesic effects during such crises (71). Actually, the decreased severity of pain by transfusions also indicates the decreased severity of inflammation all over the body. Thirdly, transfusions of lesser units of RBC suspensions in each time by means of the simple transfusions will decrease transfusion-related complications including infections, iron overload, and blood group mismatch in the future. Fourthly, transfusion of RBC suspensions in the secondary health centers may prevent some deaths developed during the transport to the tertiary centers for the exchange. Terminally, cost of the simple and repeated transfusions on insurance system is much lower than the exchange that needs trained staff and additional devices. On the other hand, pain is the result of complex and poorly understood interactions between RBC, WBC, platelets (PLT), and endothelial cells, yet. Probably, leukocytosis contributes to the pathogenesis by releasing cytotoxic enzymes. The adverse effects of WBC on vascular endothelium are of particular interest for atherosclerotic endpoints in the SCD. For instance, leukocytosis even in the absence of any infection was an independent predictor of the severity of the SCD (72), and it was associated with the risk of stroke (73). Disseminated tissue hypoxia, releasing of inflammatory mediators, bone infarctions,

and activation of afferent nerves may take role in the pathophysiology of the intolerable pain. Due to the severity of pain, narcotic analgesics are usually required (74), but according to our experiences, simple and repeated RBC transfusions may be highly effective both to relieve pain and to prevent sudden deaths which may develop secondary to multiorgan failures on the atherosclerotic endpoints of the SCD.

Hydroxyurea may be one of the life-saving drugs for the treatment of the SCD at the moment. It interferes with the cell division by blocking the formation of deoxyribonucleotides via inhibition of ribonucleotide reductase. The deoxyribonucleotides are the building blocks of DNA. Hydroxyurea mainly affects hyperproliferating cells. Although the action way of hydroxyurea is thought to be the increase in gamma-globin synthesis for fetal hemoglobin (Hb F), its main action may be the suppression of leukocytosis and thrombocytosis by blocking the DNA synthesis in the SCD (75, 76). By this way, the chronic inflammatory and destructive process of the SCD is suppressed with some extent. Due to the same action way, hydroxyurea is also used in moderate and severe psoriasis to suppress hyperproliferating skin cells. As in the viral hepatitis cases, although presence of a continuous damage of sickle cells on the capillary endothelium, the severity of destructive process is probably exaggerated by the patients' own WBC and PLT. So suppression of proliferation of them may limit the endothelial cells damage-induced edema, ischemia, and infarctions all over the body (77). Similarly, final Hb F levels in hydroxyurea users did not differ from their pretreatment levels (78). The Multicenter Study of Hydroxyurea (MSH) studied 299 severely affected adults with the SCA, and compared the results of patients treated with hydroxyurea or placebo (79). The study particularly researched effects of hydroxyurea on painful crises, ACS, and requirement of blood transfusion. The outcomes were so overwhelming in the favour of hydroxyurea group that the study was terminated after 22 months, and hydroxyurea was initiated for all patients. The MSH also demonstrated that patients treated with hydroxyurea had a 44% decrease in hospitalizations (79). In multivariable analyses, there was a strong and independent association of lower neutrophil counts with the lower crisis rates (79). But this study was performed just in severe SCA cases alone, and the rate of painful crises was decreased from 4.5 to 2.5, annually (79). Whereas we used all subtypes of the SCD with all clinical severity, and the rate of painful crises was decreased from 10.3 to 1.7, annually ($p<0.000$) with an additional decreased severity of them (7.8/10 vs 2.2/10, $p<0.000$) (66). Parallel to us, adult patients using hydroxyurea for frequent painful crises appear to have reduced mortality rate after a 9-year follow-up period (80). Although the underlying disease severity remains critical to determine prognosis, hydroxyurea may also decrease severity of disease and prolong survival (80). The complications start to be seen even in infancy in the SCD. For example, infants with lower hemoglobin values were more likely to have higher incidences of ACS, painful crises, and lower neuropsychological scores, and hydroxyurea reduced the incidences of them (81). If started in early years, hydroxyurea may protect splenic function, improve growth, and delay atherosclerotic endpoints. Although RBC transfusions can also reduce the complications, there are the risks of infections, iron overload, and development of allo-antibodies causing subsequent transfusions much more difficult. Thus RBC

transfusions should be kept just for emergencies as the most effective weapon at the moment.

Aspirin is a member of nonsteroidal anti-inflammatory drugs (NSAID). Although aspirin has similar anti-inflammatory effects with the other NSAID, it also suppresses the normal functions of PLT, irreversibly. This property causes aspirin being different from other NSAID, which are reversible inhibitors. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the cyclooxygenase (COX) enzyme. Aspirin inactivates the COX enzyme, irreversibly, which is required for the synthesis of prostaglandins (PG) and thromboxanes (TX). PG are the locally produced hormones with some diverse effects, including the transmission of pain into the brain and modulation of the hypothalamic thermostat and inflammation. TX are responsible for the aggregation of PLT to form blood clots. In another definition, low-dose aspirin irreversibly blocks the formation of TXA₂ in the PLT, producing an inhibitory effect on the PLT aggregation during whole lifespan of the affected PLT (8-9 days). Since PLT do not have nucleus and DNA, they are unable to synthesize new COX enzyme once aspirin has inhibited the enzyme. But aspirin does not decrease the blood viscosity. The antithrombotic property of aspirin is useful to reduce the risks of myocardial infarction, transient ischemic attack, and stroke (82). Heart attacks are caused primarily by blood clots, and low-dose of aspirin is seen as an effective medical intervention to prevent a second myocardial infarction (83). According to the literature, aspirin may also be effective in prevention of colorectal cancers (84). On the other hand, aspirin has some side effects including gastric ulcers, gastric bleeding, worsening of asthma, and Reye syndrome in childhood and adolescence. Due to the risk of Reye syndrome, the US Food and Drug Administration recommends that aspirin should not be prescribed for febrile patients under the age of 12 years (85). Eventually, the general recommendation to use aspirin in children has been withdrawn, and it was only recommended for Kawasaki disease (86). Reye syndrome is a rapidly worsening brain disease (86). The first detailed description of Reye syndrome was in 1963 by an Australian pathologist, Douglas Reye (87). The syndrome mostly affects children, but it can only affect fewer than one in a million children, annually (87). Symptoms of Reye syndrome may include personality changes, confusion, seizures, and loss of consciousness (86). Although the liver toxicity and enlargement typically occurs in most cases, jaundice is usually not seen (86). Although the death occurs in 20-40% of affected cases, about one third of survivors get a significant degree of brain damage (86). It usually starts just after recovery from a viral infection, such as influenza or chicken pox. About 90% of cases in children are associated with an aspirin use (87, 88). Inborn errors of metabolism are also the other risk factors, and the genetic testing for inborn errors of metabolism became available in developed countries in the 1980s (86). When aspirin use was withdrawn for children in the US and UK in the 1980s, a decrease of more than 90% in rates of Reye syndrome was seen (87). Due to the very low risk of Reye syndrome but much higher risk of death due to the SCD in children, aspirin should be added both into the acute and chronic phase treatments with an anti-inflammatory dose even in childhood in the SCD (89).

Warfarin is an anticoagulant, and it does not have any effect on blood viscosity, too. It can prevent formation of blood clots and

reduce the risk of thromboembolism. Warfarin is the best suited for anticoagulation in areas of slowly flowing blood such as veins and the pooled blood behind artificial and natural valves and dysfunctional cardiac atria. It is commonly used to prevent blood clots formation as in DVT and pulmonary embolism, and to protect against stroke in atrial fibrillation (AF), valvular heart disease, and artificial heart valves. Less commonly, it is used following ST-segment elevation myocardial infarction and orthopedic surgery. The warfarin initiation regimens are simple, safe, and suitable to be used in the ambulatory settings (90). Warfarin should be initiated with a 5 mg dose, or 2 to 4 mg in the elderly. In the protocol of low-dose warfarin, the target international normalized ratio (INR) value is between 2.0 and 2.5, whereas in the protocol of standard-dose warfarin, the target INR value is between 2.5 and 3.5 (91). When warfarin is used and INR is in therapeutic range, simple discontinuation of the drug for five days is enough to reverse the effect, and causes INR to drop below 1.5 (92). Its effects can be reversed with phytonadione (vitamin K₁), fresh frozen plasma, or prothrombin complex concentrate, rapidly. Warfarin decreases blood clotting by blocking vitamin K epoxide reductase, an enzyme that reactivates vitamin K₁. Without sufficient active vitamin K₁, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited, but to a lesser degree. A few days are required for full effect, and these effects can last for up to five days. The consensus agrees that current self-testing and management devices are effective methods of monitoring oral anticoagulation therapy, providing outcomes possibly better than achieved, clinically. The only common side effect of warfarin is hemorrhage. The risk of severe bleeding is just 1-3%, annually (93). All types of bleeding may occur, but the severest ones are those involving the central nervous system (92). The risk is particularly increased once the INR exceeds 4.5 (93). The risk of bleeding is increased further when warfarin is combined with antiplatelet drugs such as clopidogrel or aspirin (94). Thirteen publications from 11 cohorts including more than 48,500 patients with more than 11,600 warfarin users were included in the meta-analysis in which in patients with AF and non-end-stage CRD, warfarin resulted in a lower risk of ischemic stroke ($p=0.004$) and mortality ($p<0.00001$), but had no effect on major bleeding ($p>0.05$) (95). Similarly, warfarin is associated with significant reductions in ischemic stroke even in patients with warfarin-associated intracranial hemorrhage (ICH) (96). Whereas recurrent ICH occurred in 6.7% of patients who used warfarin and 7.7% of patients who did not use warfarin ($p>0.05$) (96). On the other hand, patients with cerebral venous thrombosis (CVT) anticoagulated either with warfarin or dabigatran had lower risk of recurrent venous thrombotic events (VTE), and the risks of bleeding were similar in both regimens (97). Additionally, an INR value of 1.5 achieved with an average daily dose of 4.6 mg warfarin, has resulted with no increase in the number of men ever reporting minor bleeding episodes (98). Non-rheumatic AF increases the risk of stroke, presumably from atrial thromboemboli, and long-term use of low-dose warfarin is highly effective and safe with a reduction of 86% in the risk of stroke ($p=0.0022$) (99). The mortality rate was markedly lower in the warfarin group, too ($p=0.005$) (99). The frequencies of bleedings that required hospitalization or transfusion were similar in both groups ($p>0.05$) (99). Additionally, very-low-dose warfarin was safe and effective for

prevention of thromboembolism in metastatic breast cancer in which the average daily dose was 2.6 mg, and the mean INR value was 1.5 (100). On the other hand, new oral anticoagulants had a favourable risk-benefit profile with significant reductions in stroke, ICH, and mortality, and with similar major bleedings as for warfarin, but increased GI bleeding (101). Interestingly, rivaroxaban and low-dose apixaban were associated with increased risks of all cause mortality compared with warfarin (102). The mortality rates were 4.1%, 3.7%, and 3.6% per year in the warfarin, 110 mg of dabigatran, and 150 mg of dabigatran groups, respectively ($p>0.05$ for both) with AF in another study (103). On the other hand, infection, inflammation, medical or surgical emergency, and emotional stress-induced increased basal metabolic rate accelerates sickling, and an exaggerated capillary endothelial edema-induced myocardial infarction or stroke may cause sudden deaths (104). So anti-inflammatory dose of aspirin plus low-dose warfarin may be the other life-saving regimen to decrease severity of capillary endothelial inflammation, and to prevent atherosclerotic endpoints even at childhood in the SCD (105).

COPD is the third leading cause of death in human being (106, 107). Aging, smoking, alcohol, male gender, excess fat tissue, chronic inflammation, prolonged infection, and cancers may be the major causes. Atherosclerotic effects of smoking may be the most obvious in the COPD and Buerger's disease, probably due to the higher concentrations of toxic substances in the lungs and pooling of blood in the extremities. After smoking, excess fat tissue may be the second common cause of COPD due to the excess fat tissue-induced atherosclerotic endpoints all over the body. Regular alcohol consumption may be the third leading cause of the systemic accelerated atherosclerotic process and COPD, since COPD was one of the most common diagnoses in alcohol dependence (108). Furthermore, 30-day readmission rates were higher in the COPD patients with alcoholism (109). Probably an accelerated atherosclerotic process is the main structural background of functional changes that are characteristics of the COPD. The inflammatory process of vascular endothelial cells is exaggerated by release of various chemicals by inflammatory cells, and it terminates with an advanced fibrosis, atherosclerosis, and pulmonary losses. COPD may actually be the pulmonary endpoint of the systemic atherosclerotic process. Beside the accelerated atherosclerotic process of the pulmonary vasculature, there are several reports about coexistence of associated endothelial inflammation all over the body in COPD (110). For instance, there may be close relationships between COPD, CHD, PAD, and stroke (111). Furthermore, two-third of mortality cases were caused by cardiovascular diseases and lung cancers in the COPD, and the CHD was the most common cause in a multi-center study of 5,887 smokers (112). When hospitalizations were researched, the most common causes were the cardiovascular diseases, again (112). In another study, 27% of mortality cases were due to the cardiovascular diseases in the moderate and severe COPD (113). Finally, COPD may be the pulmonary endpoint of the accelerated atherosclerotic process in the SCD (106).

Leg ulcers are seen in 10% to 20% of the SCD (114). Its prevalence increases with aging, male gender, and SCA (115). The leg ulcers have an intractable nature, and around 97% of them relapse in a period of one year (114). Similar to Buerger's disease, the leg ulcers occur in the distal segments of the body with a lesser collateral

blood flow (114). The hardened RBC-induced chronic endothelial damage, inflammation, edema, and fibrosis at the capillaries may be the major causes (115). Prolonged exposure to the hardened bodies due to the pooling of blood in the lower extremities may also explain the leg but not arm ulcers in the SCD. The hardened RBC-induced venous insufficiencies may also accelerate the process by pooling of causative bodies in the legs, and vice versa. Pooling of blood may also be important for the development of venous ulcers, diabetic ulcers, Buerger's disease, digital clubbing, and onychomycosis in the lower extremities. Furthermore, pooling of blood may be the cause of delayed wound and fracture healings in the lower extremities. Smoking and alcohol may also have some additional atherosclerotic effects on the leg ulcers in males. Hydroxyurea is the first drug that was approved by Food and Drug Administration in the SCD (116). It is an oral, cheap, safe, and effective drug that blocks cell division by suppressing formation of deoxyribonucleotides which are the building blocks of DNA (11). Its main action may be the suppression of hyperproliferative WBC and PLT in the SCD (117). Although presence of a continuous damage of hardened RBC on vascular endothelial cells, severity of the destructive process is probably exaggerated by the immune system. Similarly, lower WBC counts were associated with lower crisis rates, and if a tissue infarct occurs, lower WBC counts may decrease severity of tissue damage and pain (78). Prolonged resolution of leg ulcers with hydroxyurea may also suggest that the ulcers may be secondary to increased WBC and PLT counts-induced exaggerated capillary endothelial cell inflammation and edema.

Digital clubbing is characterized by the increased normal angle of 165° between nailbed and fold, increased convexity of the nail fold, and thickening of the whole distal finger (118). Although the exact cause and significance is unknown, the chronic tissue hypoxia is highly suspected (119). In the previous study, only 40% of clubbing cases turned out to have significant underlying diseases while 60% remained well over the subsequent years (18). But according to our experiences, clubbing is frequently associated with the pulmonary, cardiac, renal and hepatic diseases, and smoking those are characterized with chronic tissue hypoxia (5). As an explanation for that hypothesis, lungs, heart, kidneys, and liver are closely related organs which affect their functions in a short period of time. On the other hand, clubbing is also common in the SCD with a prevalence of 10.8% in the present study, too. It probably shows chronic tissue hypoxia caused by disseminated endothelial damage, edema, and fibrosis, particularly at the capillary level in the SCD. Beside the effects of SCD, smoking, alcohol, cirrhosis, CRD, CHD, and COPD, the higher prevalence of clubbing in males (14.8% vs 6.6%, $p < 0.001$) may also indicate some additional role of male gender about the atherosclerotic endpoints.

CRD is also increasing that can also be explained by aging of the human being and increased prevalence of excess weight all over the world (120). Aging, animal-rich diet, excess fat tissue, smoking, alcohol, inflammatory or infectious processes, and cancers may be the major causes of the renal endothelial inflammation. The inflammatory process is enhanced by release of various chemicals by lymphocytes to repair the damaged endothelial cells of the renal arteriols. Due to the continuous

irritation of the vascular endothelial cells, prominent changes develop in the architecture of the renal tissues with advanced atherosclerosis, tissue hypoxia, and infarcts (121). Excess fat tissue-induced hyperglycemia, dyslipidemia, elevated BP, and insulin resistance can cause tissue inflammation and immune cell activation (122). For instance, age ($p = 0.04$), high-sensitivity CRP ($p = 0.01$), mean arterial BP ($p = 0.003$), and DM ($p = 0.02$) had significant correlations with the CIMT (120). Increased renal tubular sodium reabsorption, impaired pressure natriuresis, volume expansion due to the activations of sympathetic nervous system and renin-angiotensin system, and physical compression of kidneys by visceral fat tissue may be some mechanisms of the increased BP with excess fat tissue (123). Excess fat tissue also causes renal vasodilation and glomerular hyperfiltration which initially serve as compensatory mechanisms to maintain sodium balance due to the increased tubular reabsorption (123). However, along with the increased BP, these changes cause a hemodynamic burden on the kidneys in long term that causes chronic endothelial damage (124). With prolonged excess fat tissue, there are increased urinary protein excretion, loss of nephron function, and exacerbated HT. With the development of dyslipidemia and DM, CRD progresses much more easily (123). On the other hand, the systemic inflammatory effects of smoking on endothelial cells may also be important in the CRD (125). Although some authors reported that alcohol was not related with the CRD (125), various metabolites of alcohol circulate in blood vessels of kidneys and give harm to the endothelium. Chronic inflammatory or infectious processes may also terminate with the accelerated atherosclerosis in the renal vasculature (124). Due to the systemic nature of atherosclerosis, there are close relationships between CRD and other atherosclerotic endpoints of the metabolic syndrome including CHD, COPD, PAD, cirrhosis, and stroke (126, 127). For example, the most common causes of death were the CHD and stroke in the CRD, again (128). The hardened RBC-induced capillary endothelial damage cell may be the major cause of CRD in the SCD, again (129).

Stroke is the other terminal cause of death, together with the CHD, and it develops as an acute thromboembolic event on the chronic atherosclerotic background. Aging, male gender, smoking, alcohol, excess fat tissue, chronic inflammatory or infectious processes, cancers, and emotional stress may be the major underlying causes. Stroke is also a common atherosclerotic endpoint of the SCD (130). Similar to the leg ulcers, stroke is particularly higher in cases with the SCA and higher WBC counts (131). Sickling-induced capillary endothelial damage, activations of WBC, PLT, and coagulation system, and hemolysis may terminate with chronic capillary endothelial cell damage, inflammation, edema, and fibrosis (132). Probably, stroke does not have a macrovascular origin in the SCD, and acute onset diffuse capillary endothelial cell damage, inflammation, and edema may be much more significant. Eventually, permanent neurological deficits of stroke are rare in cases with the SCD. Infection, inflammation, medical or surgical emergency, and emotional stresses may precipitate stroke by increasing basal metabolic rate and sickling. Decreased stroke with hydroxyurea can also suggest that a significant proportion of cases is developed due to the increased WBC and PLT counts-induced an acute onset accelerated capillary endothelial cell edema in the SCD (133).

Acarbose is a pseudotetrasaccharide produced as a natural microbial product of *Actinoplanes* strain SE 50. It is an alpha-glucosidase inhibitor. Acarbose binds to oligosaccharide binding site of alpha-glucosidase enzymes in the brush border of the small intestinal mucosa with a dose-dependent manner, reversibly and competitively. It inhibits glycoamylase, sucrase, maltase, dextranase, and pancreatic alpha-amylase. It has little affinity for isomaltase but does not have any effect on beta-glucosidases such as lactase. By this way, it delays the intestinal hydrolysis of oligo- and disaccharides mainly in the upper half of the small intestine. As a result, the absorption of monosaccharides is delayed, and transport into the circulation is interrupted. Actually, it does not have any direct effect on glucose absorption. It should be taken with the first bite of the meal, and its effects may prolong up to 5 hours. The suppression of alpha-glucosidases is persistent with long-term use without any treatment failure. Its usage results with carbohydrates appearing in the colon where bacterial fermentation occurs, accounting for the frequency and severity of GI adverse effects such as flatulence, loose stool, and abdominal discomfort (134). If started with a lower dosage and titrated slowly, it tends to cause tolerable GI side effects (135). Long-term use increases colonic bacterial mass that of lactobacteria in particular. The finally impaired carbohydrate absorption, increased bacterial carbohydrate fermentation, and fecal acidification mimic effects of lactulose in portosystemic encephalopathy. So acarbose has a favourable therapeutic profile for the long-term use even in cirrhosis. Similarly, observed changes in bacterial flora and decreased stool pH and beta-hydroxybutyrate may be associated with anti-proliferative effects on the epithelial cells of colon that may potentially decrease carcinogenesis. After oral administration, less than 2% of the unchanged drug enters into the circulation. Thus there is no need for dosage adjustment in mild renal insufficiency. After a high carbohydrate meal, acarbose lowers the postprandial rise in blood glucose by 20% and secondarily FPG by 15% (136). The initial improvement in blood glucose tends to be modest, but efficacy steadily improves with the long-term use, and is maintained over several years. Its beneficial effects on serum lipids were also seen with a dose-dependent manner (136), because dietary carbohydrates are key precursors of lipogenesis, and insulin plays a central role for postprandial lipid metabolism. Carbohydrate-induced postprandial triglycerides synthesis is reduced for several hours, so acarbose lowers plasma triglycerides levels (136). The same beneficial effect is also seen in non-diabetic patients with hypertriglyceridemia, and acarbose reduced LDL significantly, and HDL remained as unchanged in hyperinsulinemic and overweight patients with impaired glucose tolerance (IGT) (137). Significantly elevated ursolic acids in the stool appear to be the additive endpoint of a decreased rate of absorption and increased intestinal motility due to the changes of intestinal flora. Acarbose may lower LDL via increased fecal bifido bacteria and biliary acids. Acarbose together with insulin was identified to be associated with a greater improvement in the oxidative stress and inflammation in type 2 DM (138). Probably, acarbose improves release of glucagon-like peptide-1, inhibits PLT activation, increases epithelial nitrous oxide synthase activity and nitrous oxide concentrations, promotes weight loss, decreases BP, and eventually prevents endothelial dysfunction (136). So it prevents all atherosclerotic endpoints of excess fat even in the

absence of IGT or DM (139-141). Although some authors reported as opposite (142), it should be used as the first-line antidiabetic agent. Based on more than 40 years of use, numerous studies did not show any significant side effect or toxicity (143).

Metformin is a biguanide, and it is not metabolized, and 90% of absorbed drug is eliminated as unchanged in the urine. Plasma protein binding is negligible, so the drug is dialyzable. According to literature, antihyperglycemic effect of metformin is largely caused by inhibition of hepatic gluconeogenesis, increased insulin-mediated glucose disposal, inhibition of fatty acid oxidation, and reduction of intestinal glucose absorption (144, 145). Precise mechanism of intracellular action of metformin remains as unknown. Interestingly, 25.9% of patients stopped metformin due to the excessively lost appetite (146). Additionally, 14.1% of patients with overweight or obesity in the metformin group rose either to normal weight or overweight group by weight loss without a diet regimen (146). According to our opinion, the major effect of metformin is a powerful inhibition of appetite. Similar results indicating the beneficial effects on the BMI, BP, FPG, and lipids were also reported (147-149). Probably the major component of the metabolic syndrome may be excess fat tissue and its atherosclerotic endpoints which can be prevented by suppression of appetite. So treatment of excess fat tissue with metformin will probably prevent not only the IGT or DM but also most of the other atherosclerotic consequences. Because of the low risk of side effects, metformin can be initiated for majority of cases with excess fat, but clinicians must be careful above the age of 70 years due to risks of debility induced weight loss. Although 25.9% of patients stopped metformin due to an excessive anorexia (146), only 10.6% stopped acarbose due to an excessive flatulence or loose stool (150). So acarbose intolerance is lower than metformin in the society ($p < 0.001$) (146). Finally, acarbose can be used in a larger population than metformin, and we should not put a lower limit of age to start acarbose for cases with excess fat.

As a conclusion, hardened RBC-induced capillary endothelial damage initiated at birth terminates with multiorgan insufficiencies in early decades of life in the SCD. DM may actually be one of the atherosclerotic endpoints of the pancreas. Although all of the above atherosclerotic endpoints are frequent in the SCD, we have not detected any case of DM probably due to the significantly lower BMI of them. Similarly, just 20% of elderly have DM, but 55% of patients with DM are obese. So excess fat tissue may be much more significant than smoking, alcohol, or other chronic inflammatory or infectious processes for the systemic atherosclerosis. Acarbose and metformin are safe, cheap, oral, long-term used, and effective drugs for loss of excess fat tissue.

References

1. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol* 2003; 42(7): 1149-60.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. *Lancet* 2005; 365(9468): 1415-28.
3. Franklin SS, Barboza MG, Pio JR, Wong ND. Blood pressure categories, hypertensive subtypes, and the metabolic syndrome. *J Hypertens* 2006; 24(10): 2009-16.
4. Third Report of the National Cholesterol Education Program

- (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation* 2002; 106(25): 3143-421.
5. Helvacı MR, Aydın LY, Aydın Y. Digital clubbing may be an indicator of systemic atherosclerosis even at microvascular level. *HealthMED* 2012; 6(12): 3977-81.
 6. Anderson RN, Smith BL. Deaths: leading causes for 2001. *Natl Vital Stat Rep* 2003; 52(9): 1-85.
 7. Helvacı MR, Gökçe C, Davran R, Akkucuk S, Ugur M, Oruc C. Mortal quintet of sickle cell diseases. *Int J Clin Exp Med* 2015; 8(7): 11442-8.
 8. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med* 1994; 330(23): 1639-44.
 9. Helvacı MR, Yaprak M, Abyad A, Pocock L. Atherosclerotic background of hepatosteatosis in sickle cell diseases. *World Family Med* 2018; 16(3): 12-8.
 10. Helvacı MR, Kaya H. Effect of sickle cell diseases on height and weight. *Pak J Med Sci* 2011; 27(2): 361-4.
 11. Helvacı MR, Aydın Y, Ayyıldız O. Hydroxyurea may prolong survival of sickle cell patients by decreasing frequency of painful crises. *HealthMED* 2013; 7(8): 2327-32.
 12. Mankad VN, Williams JP, Harpen MD, Mancini E, Longenecker G, Moore RB, et al. Magnetic resonance imaging of bone marrow in sickle cell disease: clinical, hematologic, and pathologic correlations. *Blood* 1990; 75(1): 274-83.
 13. Helvacı MR, Aydın Y, Ayyıldız O. Clinical severity of sickle cell anemia alone and sickle cell diseases with thalassemias. *HealthMED* 2013; 7(7): 2028-33.
 14. Fisher MR, Forfia PR, Chamara E, Houston-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care Med* 2009; 179(7): 615-21.
 15. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2013; 187(4): 347-65.
 16. Davies SC, Luce PJ, Win AA, Riordan JF, Brozovic M. Acute chest syndrome in sickle-cell disease. *Lancet* 1984; 1(8367): 36-8.
 17. Vandemergel X, Renneboog B. Prevalence, aetiologies and significance of clubbing in a department of general internal medicine. *Eur J Intern Med* 2008; 19(5): 325-9.
 18. Schamroth L. Personal experience. *S Afr Med J* 1976; 50(9): 297-300.
 19. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. *N Engl J Med* 1999; 341(15): 1097-105.
 20. Helvacı MR, Aydın Y, Gundogdu M. Smoking induced atherosclerosis in cancers. *HealthMED* 2012; 6(11): 3744-9.
 21. Ross R. Atherosclerosis--an inflammatory disease. *N Engl J Med* 1999; 340(2): 115-26.
 22. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. *Circulation* 2001; 103(13): 1813-8.
 23. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. *JAMA* 1998; 279(18): 1477-82.
 24. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 1999; 282(22): 2131-5.
 25. Zhou B, Wu Y, Yang J, Li Y, Zhang H, Zhao L. Overweight is an independent risk factor for cardiovascular disease in Chinese populations. *Obes Rev* 2002; 3(3): 147-56.
 26. Zhou BF. Effect of body mass index on all-cause mortality and incidence of cardiovascular diseases--report for meta-analysis of prospective studies open optimal cut-off points of body mass index in Chinese adults. *Biomed Environ Sci* 2002; 15(3): 245-52.
 27. Helvacı MR, Kaya H, Yalcin A, Kuvandik G. Prevalence of white coat hypertension in underweight and overweight subjects. *Int Heart J* 2007; 48(5): 605-13.
 28. Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. *Am J Clin Nutr* 2003; 78(3): 361-9.
 29. Fodor JG, Tzerovska R, Dorner T, Rieder A. Do we diagnose and treat coronary heart disease differently in men and women? *Wien Med Wochenschr* 2004; 154(17-18): 423-5.
 30. Helvacı MR, Aydın LY, Aydın Y. Chronic obstructive pulmonary disease may be one of the terminal end points of metabolic syndrome. *Pak J Med Sci* 2012; 28(3): 376-9.
 31. Helvacı MR, Kayabasi Y, Celik O, Sencan H, Abyad A, Pocock L. Smoking causes a moderate or severe inflammatory process in human body. *Am J Biomed Sci & Res* 2023; 7(6): 694-702.
 32. Grunberg NE, Greenwood MR, Collins F, Epstein LH, Hatsukami D, Niaura R, et al. National working conference on smoking and body weight. Task Force 1: Mechanisms relevant to the relations between cigarette smoking and body weight. *Health Psychol* 1992; 11: 4-9.
 33. Helvacı MR, Camci C, Nisa EK, Ersahin T, Atabay A, Alrawii I, Ture Y, Abyad A, Pocock L. Severity of sickle cell diseases restricts smoking. *Ann Med Medical Res* 2024; 7: 1074.
 34. Walker JF, Collins LC, Rowell PP, Goldsmith LJ, Moffatt RJ, Stamford BA. The effect of smoking on energy expenditure and plasma catecholamine and nicotine levels during light physical activity. *Nicotine Tob Res* 1999; 1(4): 365-70.
 35. Hughes JR, Hatsukami DK. Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight. *J Subst Abuse* 1997; 9: 151-9.
 36. Miyata G, Meguid MM, Varma M, Fetisov SO, Kim HJ. Nicotine alters the usual reciprocity between meal size and meal number in female rat. *Physiol Behav* 2001; 74(1-2): 169-76.
 37. Froom P, Melamed S, Benbassat J. Smoking cessation and weight gain. *J Fam Pract* 1998; 46(6): 460-4.
 38. Helvacı MR, Kaya H, Gundogdu M. Gender differences in coronary heart disease in Turkey. *Pak J Med Sci* 2012; 28(1): 40-4.
 39. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. *BMJ* 1998; 316(7137): 1043-7.
 40. Helvacı MR, Kabay S, Gulcan E. A physiologic events' cascade, irritable bowel syndrome, may even terminate with

- urolithiasis. *J Health Sci* 2006; 52(4): 478-81.
41. Helvacı MR, Dede G, Yildirim Y, Salaz S, Abyad A, Pocock L. Smoking may even cause irritable bowel syndrome. *World Family Med* 2019; 17(3): 28-33.
 42. Helvacı MR, Algin MC, Kaya H. Irritable bowel syndrome and chronic gastritis, hemorrhoid, urolithiasis. *Eurasian J Med* 2009; 41(3): 158-61.
 43. Kamimura D, Loprinzi PD, Wang W, Suzuki T, Butler KR, Mosley TH, et al. Physical activity is associated with reduced left ventricular mass in obese and hypertensive African Americans. *Am J Hypertens* 2017; 30(6): 617-23.
 44. [Sun Z](#), [Lazar MA](#). Dissociating fatty liver and diabetes. *Trends Endocrinol Metab* 2013; 24(1): 4-12.
 45. [Rastogi A](#), [Sakhuja P](#), [Kumar A](#), [Hissar S](#), [Jain A](#), [Gondal R](#), et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. *Indian J Pathol Microbiol* 2011; 54(3): 454-9.
 46. [Köse D](#), [Erol C](#), [Kaya F](#), [Koplay M](#), [Köksal Y](#). Development of fatty liver in children with non-Hodgkin lymphoma. *Turk J Pediatr* 2014; 56(4): 399-403.
 47. [Aktas E](#), [Uzman M](#), [Yildirim O](#), [Sahin B](#), [Buyukcam F](#), [Aktas B](#), et al. Assessment of hepatic steatosis on contrast enhanced computed tomography in patients with colorectal cancer. *Int J Clin Exp Med* 2014; 7(11): 4342-6.
 48. [Balcik OS](#), [Akdeniz D](#), [Cipil H](#), [Ikizek M](#), [Uysal S](#), [Kosar A](#), et al. Serum thrombopoietin levels in patients with non-alcoholic fatty liver disease. *Saudi Med J* 2012; 33(1): 30-3.
 49. [Çiftçi A](#), [Yilmaz B](#), [Köklü S](#), [Yüksel O](#), [Özsoy M](#), [Erden G](#), et al. Serum levels of nitrate, nitrite and advanced oxidation protein products (AOPP) in patients with nonalcoholic fatty liver disease. *Acta Gastroenterol Belg* 2015; 78(2): 201-5.
 50. [Kucukazman M](#), [Ata N](#), [Yavuz B](#), [Dal K](#), [Sen O](#), [Deveci OS](#), et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* 2013; 25(2): 147-51.
 51. [Agaç MT](#), [Korkmaz L](#), [Cavusoglu G](#), [Karadeniz AG](#), [Agaç S](#), [Bektas H](#), et al. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study. *Angiology* 2013; 64(8): 604-8.
 52. [İnci ME](#), [Özkan F](#), [Ark B](#), [Vurdem ÜE](#), [Ege MR](#), [Sincer I](#), et al. Sonographic evaluation for predicting the presence and severity of coronary artery disease. *Ultrasound Q* 2013; 29(2): 125-30.
 53. [Öztürk H](#), [Gümrükçüoğlu HA](#), [Yaman M](#), [Akyol A](#), [Öztürk S](#), [Akdağ S](#), et al. Hepatosteatois and carotid intima-media thickness in patients with myocardial infarction. *J Med Ultrason (2001)* 2016; 43(1): 77-82.
 54. [Karasin M](#), [Tokgoz O](#), [Serifoglu I](#), [Oz I](#), [Erdem O](#). The Doppler ultrasonographic evaluation of hemodynamic changes in hepatic vascular structures in patients with hepatosteatois. *Pol J Radiol* 2014; 79: 299-304.
 55. Ozbulbul NI, Yurdakul M, Tola M. Does the visceral fat tissue show better correlation with the fatty replacement of the pancreas than with BMI? *Eurasian J Med* 2010; 42(1): 24-7.
 56. Van Geenen EJ, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ. Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. *Pancreas* 2010; 39(8): 1185-90.
 57. Stamm BH. Incidence and diagnostic significance of minor pathologic changes in the adult pancreas at autopsy: a systematic study of 112 autopsies in patients without known pancreatic disease. *Hum Pathol* 1984; 15(7): 677-83.
 58. Lameloise N, Muzzin P, Prentki M, Assimacopoulos-Jeannet F. Uncoupling protein 2: a possible link between fatty acid excess and impaired glucose-induced insulin secretion? *Diabetes* 2001; 50(4): 803-9.
 59. Aubert A, Garnet JM, Hammel P, Levy P, O'Toole D, Ruszniewski P, et al. Diffuse primary fat replacement of the pancreas: an unusual cause of steatorrhea. *Gastroenterol Clin Biol* 2007; 31(3): 303-6.
 60. Chai J, Liu P, Jin E, Su T, Zhang J, Shi K, et al. MRI chemical shift imaging of the fat content of the pancreas and liver of patients with type 2 diabetes mellitus. *Exp Ther Med* 2016; 11(2): 476-80.
 61. Quintero JHR, Grosser R, Velez GR, Ramos-Santillan VO, Pereira X, Flores FM, et al. Safety and efficacy of roux-en-y gastric bypass in older aged patients. *Rev Col Bras Cir* 2022; 49: e20223332.
 62. Kim MK, Chun HJ, Park JH, Yea DM, Baek KH, Song KH, et al. The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes. *Diabetes Res Clin Pract* 2014; 106(3): 590-6.
 63. Selim Kul, Ayşegül Karadeniz, İhsan Dursun, Sinan Şahin, Ömer Faruk Çırakoğlu, Muhammet Raşit Sayın, et al. Non-Alcoholic Fatty Pancreas Disease is associated with Increased Epicardial Adipose Tissue and Aortic Intima-Media Thickness. *Acta Cardiol Sin* 2019; 35(2): 118-25.
 64. Pezzilli R, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? *World J Diabetes* 2014; 5(4): 415-9.
 65. Parfrey NA, Moore W, Hutchins GM. Is pain crisis a cause of death in sickle cell disease? *Am J Clin Pathol* 1985; 84(2): 209-12.
 66. Helvacı MR, Ayyıldız O, Gundogdu M. Hydroxyurea therapy and parameters of health in sickle cell patients. *HealthMED* 2014; 8(4): 451-6.
 67. Helvacı MR, Tonyali O, Yaprak M, Abyad A, Pocock L. Increased sexual performance of sickle cell patients with hydroxyurea. *World Family Med* 2019; 17(4): 28-33.
 68. Helvacı MR, Aydın Y, Aydın LY, Sevinc A, Camci C, Abyad A, Pocock L. Red blood cell transfusions should be preserved just for emergencies in sickle cell diseases. *World Family Med* 2025; 23(4): 40-53.
 69. Helvacı MR, Atci N, Ayyıldız O, Muftuoglu OE, Pocock L. Red blood cell supports in severe clinical conditions in sickle cell diseases. *World Family Med* 2016; 14(5): 11-8.
 70. Helvacı MR, Ayyıldız O, Gundogdu M. Red blood cell transfusions and survival of sickle cell patients. *HealthMED* 2013; 7(11): 2907-12.
 71. Helvacı MR, Cayir S, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Red blood cell transfusions may have the strongest analgesic effect during acute painful crises in sickle cell diseases. *Ann Clin Med Case Rep* 2024; V13(12): 1-12.
 72. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. *N Engl J Med* 2000; 342(2): 83-9.
 73. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE,

- Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. *J Pediatr* 1992; 120(3): 360-6.
74. Cole TB, Sprinkle RH, Smith SJ, Buchanan GR. Intravenous narcotic therapy for children with severe sickle cell pain crisis. *Am J Dis Child* 1986; 140(12): 1255-9.
 75. Miller BA, Platt O, Hope S, Dover G, Nathan DG. Influence of hydroxyurea on fetal hemoglobin production in vitro. *Blood* 1987; 70(6): 1824-9.
 76. Platt OS. Is there treatment for sickle cell anemia? *N Engl J Med* 1988; 319(22): 1479-80.
 77. Helvacı MR, Aydoğan F, Sevinc A, Camcı C, Dilek I. Platelet and white blood cell counts in severity of sickle cell diseases. *Pren Med Argent* 2014; 100(1): 49-56.
 78. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. *Semin Hematol* 1997; 34(3): 15-21.
 79. Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *Medicine (Baltimore)* 1996; 75(6): 300-26.
 80. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA* 2003; 289(13): 1645-51.
 81. Lebensburger JD, Miller ST, Howard TH, Casella JF, Brown RC, Lu M, et al; BABY HUG Investigators. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. *Pediatr Blood Cancer* 2012; 59(4): 675-8.
 82. Toghi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. *Stroke* 1992; 23(10): 1400-3.
 83. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009; 373(9678): 1849-60.
 84. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. *Lancet Oncol* 2012; 13(5): 518-27.
 85. Macdonald S. Aspirin use to be banned in under 16 year olds. *BMJ* 2002; 325(7371): 988.
 86. Schrör K. Aspirin and Reye syndrome: a review of the evidence. *Paediatr Drugs* 2007; 9(3): 195-204.
 87. Pugliese A, Beltramo T, Torre D. Reye's and Reye's-like syndromes. *Cell Biochem Funct* 2008; 26(7): 741-6.
 88. Hurwitz ES. Reye's syndrome. *Epidemiol Rev* 1989; 11: 249-53.
 89. Meremikwu MM, Okomo U. Sickle cell disease. *BMJ Clin Evid* 2011; 2011: 2402.
 90. Mohamed S, Fong CM, Ming YJ, Kori AN, Wahab SA, Ali ZM. Evaluation of an initiation regimen of warfarin for international normalized ratio target 2.0 to 3.0. *J Pharm Technol* 2021; 37(6): 286-92.
 91. Chu MWA, Ruel M, Graeve A, Gerdisch MW, Ralph J, Damiano Jr RJ, Smith RL. Low-dose vs standard warfarin after mechanical mitral valve replacement: A randomized trial. *Ann Thorac Surg* 2023; 115(4): 929-38.
 92. Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneously vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. *Ann Intern Med* 2002; 137(4): 251-4.
 93. Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. *J Am Acad Dermatol* 2015; 72(3): 524-34.
 94. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. *CMAJ* 2007; 177(4): 347-51.
 95. Dahal K, Kunwar S, Rijal J, Schulman P, Lee J. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. *Chest* 2016; 149(4): 951-9.
 96. Chai-Adisaksopha C, Lorio A, Hillis C, Siegal D, Witt DM, Schulman S, et al. Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. *Thromb Res* 2017; 160: 97-104.
 97. Ferro JM, Coutinho JM, Dentali F, Kobayashi A, Alasheev A, Canhao P, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: A randomized clinical trial. *JAMA Neurol* 2019; 76(12): 1457-65.
 98. Meade TW. Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. *Am J Cardiol* 1990; 65(6): 7C-11C.
 99. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, et al. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med* 1990; 323(22): 1505-11.
 100. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanya A, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. *Lancet* 1994; 343(8902): 886-9.
 101. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; 383(9921): 955-62.
 102. Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. *BMJ* 2018; 362: k2505.
 103. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009; 361(12): 1139-51.
 104. Helvacı MR, Cayir S, Halici H, Sevinc A, Camcı C, Abyad A, Pocock L. Terminal endpoints of systemic atherosclerotic processes in sickle cell diseases. *World Family Med* 2024; 22(5): 13-23.
 105. Helvacı MR, Daglioglu MC, Halici H, Sevinc A, Camcı C, Abyad A, Pocock L. Low-dose aspirin plus low-dose warfarin may be the standard treatment regimen in Buerger's disease.

- World Family Med 2024; 22(6): 22-35.
106. Helvaci MR, Erden ES, Aydin LY. Atherosclerotic background of chronic obstructive pulmonary disease in sickle cell patients. *HealthMED* 2013; 7(2): 484-8.
 107. Rennard SI, Drummond MB. Early chronic obstructive pulmonary disease: definition, assessment, and prevention. *Lancet* 2015; 385(9979): 1778-88.
 108. Schoepf D, Heun R. Alcohol dependence and physical comorbidity: Increased prevalence but reduced relevance of individual comorbidities for hospital-based mortality during a 12.5-year observation period in general hospital admissions in urban North-West England. *Eur Psychiatry* 2015; 30(4): 459-68.
 109. Singh G, Zhang W, Kuo YF, Sharma G. Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. *Chest* 2016; 149(4): 905-15.
 110. Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al. The natural history of chronic obstructive pulmonary disease. *Eur Respir J* 2006; 27(3): 627-43.
 111. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. *Arch Intern Med* 2000; 160(17): 2653-58.
 112. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. *Am J Respir Crit Care Med* 2002; 166(3): 333-9.
 113. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. *Thorax* 2007; 62(5): 411-5.
 114. Trent JT, Kirsner RS. Leg ulcers in sickle cell disease. *Adv Skin Wound Care* 2004; 17(8): 410-6.
 115. Minniti CP, Eckman J, Sebastiani P, Steinberg MH, Ballas SK. Leg ulcers in sickle cell disease. *Am J Hematol* 2010; 85(10): 831-3.
 116. Yawn BP, Buchanan GR, Afeniyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. *JAMA* 2014; 312(10): 1033-48.
 117. Helvaci MR, Aydogan F, Sevinc A, Camci C, Dilek I. Platelet and white blood cell counts in severity of sickle cell diseases. *HealthMED* 2014; 8(4): 477-82.
 118. Myers KA, Farquhar DR. The rational clinical examination. Does this patient have clubbing? *JAMA* 2001; 286(3): 341-7.
 119. Toovey OT, Eisenhauer HJ. A new hypothesis on the mechanism of digital clubbing secondary to pulmonary pathologies. *Med Hypotheses* 2010; 75(6): 511-3.
 120. Nassiri AA, Hakemi MS, Asadzadeh R, Faizei AM, Alatab S, Miri R, et al. Differences in cardiovascular disease risk factors associated with maximum and mean carotid intima-media thickness among hemodialysis patients. *Iran J Kidney Dis* 2012; 6(3): 203-8.
 121. Helvaci MR, Gokce C, Sahan M, Hakimoglu S, Coskun M, Gozukara KH. Venous involvement in sickle cell diseases. *Int J Clin Exp Med* 2016; 9(6): 11950-7.
 122. Xia M, Guerra N, Sukhova GK, Yang K, Miller CK, Shi GP, et al. Immune activation resulting from NKG2D/ligand interaction promotes atherosclerosis. *Circulation* 2011; 124(25): 2933-43.
 123. Hall JE, Henegar JR, Dwyer TM, Liu J, da Silva AA, Kuo JJ, et al. Is obesity a major cause of chronic kidney disease? *Adv Ren Replace Ther* 2004; 11(1): 41-54.
 124. Nerpin E, Ingelsson E, Risérus U, Helmersson-Karlqvist J, Sundström J, Jobs E, et al. Association between glomerular filtration rate and endothelial function in an elderly community cohort. *Atherosclerosis* 2012; 224(1): 242-6.
 125. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. *Epidemiology* 2003; 14(4): 479-87.
 126. Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. *Nat Rev Gastroenterol Hepatol* 2012; 9(7): 372-81.
 127. Helvaci MR, Cayir S, Halici H, Sevinc A, Camci C, Sencan H, Davran R, Abyad A, Pocock L. Acute chest syndrome and coronavirus disease may actually be genetically determined exaggerated immune response syndromes particularly in pulmonary capillaries. *World Family Med* 2024; 22(3): 6-16.
 128. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol* 2006; 17(7): 2034-47.
 129. Helvaci MR, Aydin Y, Aydin LY. Atherosclerotic background of chronic kidney disease in sickle cell patients. *HealthMED* 2013; 7(9): 2532-7.
 130. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. *N Engl J Med* 2014; 371(8): 699-710.
 131. Majumdar S, Miller M, Khan M, Gordon C, Forsythe A, Smith MG, et al. Outcome of overt stroke in sickle cell anaemia, a single institution's experience. *Br J Haematol* 2014; 165(5): 707-13.
 132. Kossorotoff M, Grevent D, de Montalembert M. Cerebral vasculopathy in pediatric sickle-cell anemia. *Arch Pediatr* 2014; 21(4): 404-14.
 133. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. *N Engl J Med* 1995; 332(20): 1317-22.
 134. Rosak C, Mertes G. Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. *Diabetes Metab Syndr Obes* 2012; 5: 357-67.
 135. Salvatore T, Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. *Clin Pharmacokinet* 1996; 30(2): 94-106.
 136. DiNicolantonio JJ, Bhutani J, O'Keefe JH. Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. *Open Heart* 2015; 2(1): e000327.
 137. Leonhardt W, Hanefeld M, Fischer S, Schulze J. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. *Eur J Clin Invest* 1994; 24(3): 45-9.
 138. Li FF, Fu LY, Xu XH, Su XF, Wu JD, Ye L, et al. Analysis of the add-on effect of alpha-glucosidase inhibitor, acarbose in insulin therapy: A pilot study. *Biomed Rep* 2016; 5(4): 461-6.

139. Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR. What does postprandial hyperglycaemia mean? *Diabet Med* 2004; 21(3): 208-13.
140. Standl E, Schnell O, Ceriello A. Postprandial hyperglycemia and glycemic variability: should we care? *Diabetes Care* 2011; 34(2): 120-7.
141. Helvaci MR, Halici H, Erdogan K, Sevinc A, Camci C, Abyad A, Pocock L. Acarbose in the treatment of chronic obstructive pulmonary disease. *World Family Med* 2025; 23(2): 37-52.
142. Wettergreen SA, Sheth S, Malveaux J. Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus. *Pharm Pract (Granada)* 2016; 14(4): 832.
143. Van De Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care* 2005; 28(1): 154-63.
144. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. *N Engl J Med* 1995; 333(9): 550-554.
145. Jackson RA, Hawa MI, Jaspan JB, Sim BM, Disilvio L, Featherbe D, et al. Mechanism of metformin action in non-insulin-dependent diabetes. *Diabetes* 1987; 36(5): 632-640.
146. Helvaci MR, Kaya H, Borazan A, Ozer C, Seyhanli M, Yalcin A. Metformin and parameters of physical health. *Intern Med* 2008; 47(8): 697-703.
147. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. *Diabetes Metab Rev* 1995; 11(1): 57-62.
148. Wu MS, Johnston P, Sheu WH, Hollenbeck CB, Jeng CY, Goldfine ID, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. *Diabetes Care* 1990; 13(1): 1-8.
149. Helvaci MR, Kurt GD, Halici H, Sevinc A, Camci C, Abyad A, Pocock L. Metformin in the treatment of chronic renal disease. *World Family Med* 2025; 23(1): 12-27.
150. Helvaci MR, Aydin Y, Varan G, Abyad A, Pocock L. Acarbose versus metformin in the treatment of metabolic syndrome. *World Family Med* 2018; 16(5): 10-15.